UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000043840 |
|---|---|
| Receipt number | R000050034 |
| Scientific Title | General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphoma- |
| Date of disclosure of the study information | 2021/05/19 |
| Last modified on | 2023/11/16 10:32:47 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2021/04/05 10:18:43 | ||
| 2 | Update | 2021/05/19 12:19:46 | Narrative objectives1 |
|
| 3 | Update | 2021/05/19 12:21:10 | Date of disclosure of the study information |
|
| 4 | Update | 2021/05/19 12:23:42 | Recruitment status Date of IRB Anticipated trial start date |
|
| 5 | Update | 2022/01/07 13:24:17 | Division name Division name TEL Division name Division name TEL Division name Division name TEL |
|
| 6 | Update | 2022/12/28 06:55:09 | Email |
|
| 7 | Update | 2023/05/30 17:11:07 | Email |
|
| 8 | Update | 2023/11/16 10:17:09 | Recruitment status |
|
| 9 | Update | 2023/11/16 10:32:47 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
